giardiasis/headache

During the period from March through November 1989, 70 children who were attended at the Pediatric Department at Central Hospital in Valencia, were enrolled in the study, it was thought that Giardia lamblia infection might be present. Giardia L. were identified using two different diagnostic

The main symptoms of infection with Giardia intestinalis in 33 Sudanese adults were abdominal pain, flatulence and diarrhoea. Other symptoms were offensive stools, loss of weight, milk intolerance, mucoid stools, nausea and vomiting. Tinidazole given orally as 150 mg. twice daily dose for seven days

A randomized controlled trial, 113 school children with Giardia intestinalis infection were treated with albendazole or tinidazole. Albendazole 400 mg once a day x 3 days and tinidazole 50 mg/kg single dose were given orally to 62 and 51 children, respectively. Parasitological cure was documented

Chronic or recurrent abdominal pain constitutes a serious diagnostic and therapeutic problem in childhood. The gastrointestinal, biliary tract or renal lesions often produce the chronic abdominal pain in children. Among causative factors of the chronic abdominal pain the infection with Giardia

The author treated 100 patients infected by Giardia lamblia with a new antiprotozoal agent: Tinidazole. The patients were divided in two groups: Group I, composed of 50 patients were divided with a dosage of 300 mgm per day for seven consecutive days. The author obtained a cure rate of 96% (48

BACKGROUND Giardia duodenalis is among the commonest protozoan parasites in the intestinal tract of humans and may cause significant morbidity worldwide. Although there are several antigiardial agents, treatment failures have been commonly reported. OBJECTIVE To compare the efficacy and safety of

BACKGROUND Giardia duodenalis is the most commonly detected parasite in the intestinal tract of humans and 5-nitroimidazole compounds, quinacrine and furazolidone have been used against giardiasis. However, cases refractory to treatment with these drugs are becoming more common

Ornidazole (Tiberal La Roche) was used in 50 persons infected with Giardia intestinalis in the doses of 500 mg twice a day during 5 days. Examinations were performed after 7-10 days, having been repeated one month and 3 months later. A positive results were achieved after one month in 46 cases (92%)

BACKGROUND Albendazole (ABZ) is a benzimidazole carbamate compound currently in use for human medical practice against enterobiasis and soil-transmitted helminthiasis (STH); However, its spectrum of activity is broad and goes beyond these infections. OBJECTIVE This study compares the efficacy and

Cryptosporidium spp. and Giardia lamblia (synonyms: Giardia duodenalis, Giardia intestinalis) are emerging protozoa causing disease in humans and animals worldwide. These parasites can pose a serious threat to immunocompromised people, for whom the symptoms are more severe and may include abdominal

BACKGROUND Giardiasis is one of the most common causes of diarrheal disease worldwide and 5-nitroimidazoles (5-NI) are the most commonly prescribed drugs for the treatment of giardiasis. We evaluated the efficacy of 5-nitroimidazoles (5-NI) in the treatment of giardiasis in a systematic review of

Giardia lamblia is an intestinal parasite that has an extensive genetic variation among isolates. This species is divided into eight different assemblages (A-H), but only assemblages A and B have been associated with human infections. Studies on the associations of G. lamblia assemblages and

The Centers for Disease Control and Prevention estimates that each year, one in six Americans will experience a foodborne illness. The most common causes in the United States are viruses, such as norovirus; bacteria, such as Salmonella, Escherichia coli, Campylobacter, and Listeria; and parasites,

The efficacy of albendazole (400 mg taken once), mebendazole (100 mg taken once), and metronidazole (0.5 g thrice daily for 7 days) was evaluated when treating ascariasis, enterobiosis, and blastocystosis, respectively, in patients with HIV infection and in those with pulmonary tuberculosis.

Go.10213, a new nitroimidazole, was studied in 12 male volunteers for tolerability and in 20 patients with intestinal amoebiasis for antiamoebic activity. Go.10213 was well-tolerated by volunteers up to a dose of 400 mg X 3. Patients also tolerated well the dose of 100-150 mg X 3 for 7 days. In two